Study of Oral MRT-2359 in Selected Cancer Patients
M
Mateusz Opyrchal, MD, PhD
18-100 years
All genders
Phase 1/2
Interventional
This Phase 1/2, open-label, multicenter study is conducted in patients with previouslyd selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung(SCLC), high-grade neuroendocrine cancer of any primary site, diffuse large B-cellymphoma (DLBCL), and tumors with L-MYC or N-MYC amplification. Patients receive escalating doses of a GSPT1 molecular …